Ignite Creation Date:
2024-05-06 @ 2:23 PM
Last Modification Date:
2024-10-26 @ 1:30 PM
Study NCT ID:
NCT04309981
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-28
First Post:
2020-03-09
Brief Title:
Clinical Trial Using Humanized CART Directed Against BCMA ARI0002h in Patients With RelapsedRefractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti-CD38 Antibody
Sponsor:
Sara V Latorre
Organization:
Institut dInvestigacions Biomèdiques August Pi i Sunyer
Study Overview
Official Title:
Pilot Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-BCMA TNFRSF17 Specificity Humanized Conjugated With the Co-stimulatory Region 4-1BB and Signal-transduction CD3z ARI0002h in Patients With RelapsedRefractory Multiple Myeloma With Previous Treatment With Proteasome Inhibitor Immunomodulatory Drug and Anti-CD38 Monoclonal Antibody
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsedrefractory multiple myeloma who have received treatment with proteasome inhibitor immunomodulatory drug and anti-CD38 monoclonal antibody
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-001472-11 | EUDRACT_NUMBER | None | None |